HealthyDirect · GrowthFit for a long SIP
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund
- NAV
- 25.2802
- 30 Oct 2026
- 1Y
- +20.9%
- Trailing CAGR
- AUM
- ₹191.85 Cr
- 30 Sept 2026
- Volatility
- Medium
- 12.0% annualized
Buying brief
Should you add this fund?
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
In three lines
Fits if · The fund beat the category median in 66% of rolling 3-year windows.
Fits if · Three-year return is above the category median.
Buy checklist
History depth
Pass
6.0 years of path to read.
Engine status
Pass
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Expense ratio
Pass
0.56% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -16.3%. Ask whether you can hold through a similar fall.
Vs category
Pass
66% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
n/a
Manager not listed.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 55.0% of the portfolio.
Evidence supports a shortlist - confirm with peers before you buy elsewhere.
Before you buy or SIP
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 16%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
If you start a SIP here, diary a 90-day check and an annual review - don’t react to every NAV print.
NAV
Path not in current snapshots
n/a
Returns
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
- 1Y+20.9%
- 3Y+22.1%
- 5Y+15.1%
- 10Yn/a
- SI+16.8%
SIP XIRR
Equal monthly instalments to latest NAV
- 1Y+25.0%
- 3Y+17.3%
- 5Y+18.4%
- 10Yn/a
- Since inception
- +16.8%
- Calendar-day CAGR
- Excess 1Y
- +23.5%
- Category median, same plan and option
- 3Y win rate
- +66%
- Windows beating the median
- 3Y percentile
- 97
- Vs comparable share classes
- SIP 3Y XIRR
- +17.3%
- Simulated monthly SIP
- Worst rolling 3Y
- +11.0%
- 713 daily-ending windows
- Median rolling 3Y
- +17.7%
- Calendar-day CAGR
- Positive rolling 5Y
- +100%
- 238 daily-ending windows
Drawdown
Peak to trough from a running NAV high, with the path and recovery episodes.
- Max drawdown
- -16.3%
- Worst peak-to-trough
- Current
- 0.0%
- At peak
- Current spell
- 0 days
- Days below latest peak
- Time below peak
- +88%
- NAV observations
Drawdown
Path not in current snapshots
n/a
- Average recovery
- 14 days
- 73 recovered episodes
- Longest recovery
- 363 days
- Trough to prior peak
3 Sept 2021 – 15 Jun 2023
Trough 17 Jun 2022 · recovered in 363 days
-16.3%
9 Oct 2024 – 17 Oct 2025
Trough 7 Apr 2025 · recovered in 193 days
-12.2%
11 Jan 2021 – 9 Apr 2021
Trough 18 Mar 2021 · recovered in 22 days
-9.0%
26 Feb 2026 – 14 May 2026
Trough 6 Apr 2026 · recovered in 38 days
-6.6%
Dimensions
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
97
Vs category
100
Consistency
62
Risk-adjusted
72
Drawdown
59
Mean
78
Decision
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Healthy
Buying stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Why this status
- No material deterioration, cost shock, or persistent category underperformance in the current evidence set.
Supporting reads
- The fund beat the category median in 66% of rolling 3-year windows.
- Three-year return is above the category median.
- Risk-adjusted return sits above the documented risk-free proxy.
Portfolio
30 Sept 2026 · 46 holdings · top 10 are 55.0%.
- Top 5
- 33.7%
- Top 10
- 55.0%
- Largest holding
- 10.4%
- Effective holdings
- 23.9
Sun Pharmaceutical Industries Ltd
Healthcare
10.4%
Divi's Laboratories Ltd
Healthcare
7.1%
Eli Lilly Forgn. Eq (LLY)
Healthcare
6.5%
Apollo Hospitals Enterprise Ltd
Healthcare
5.3%
Johnson & Johnson Ltd. Forgn. Eq (JNJ)
Healthcare
4.5%
Worth investigating
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Edelweiss CRISIL IBX AAA Financial Services Bond - Jan 2028 Index Fund
Edelweiss Mutual Fund
- 1Y
- +5.4%
- 3Y
- n/a
- Vol
- 0.9%
- Max DD
- -0.5%
- Sharpe
- 1.36
- 3Y win
- n/a
- Lower volatility
- Shallower drawdown
- Higher win rate vs category
- Lower TER
Caveat: Lower trailing returns
Kotak CRISIL-IBX Financial Services 3-6 Months Debt Index Fund
Kotak Mahindra Mutual Fund
- 1Y
- +6.5%
- 3Y
- n/a
- Vol
- 0.4%
- Max DD
- -0.2%
- Sharpe
- 2.28
- 3Y win
- n/a
- Lower volatility
- Shallower drawdown
- Higher win rate vs category
- Lower TER
Caveat: Lower trailing returns
Nippon India Nifty India Manufacturing Index Fund
Nippon India Mutual Fund
- 1Y
- -2.0%
- 3Y
- n/a
- Vol
- 15.2%
- Max DD
- -12.8%
- Sharpe
- -0.04
- 3Y win
- n/a
- Shallower drawdown
- Higher win rate vs category
- Lower TER
Caveat: Higher volatility · Lower trailing returns
Aditya Birla Sun Life Crisil IBX Gilt Apr 2028 Index Fund
Aditya Birla Sun Life Mutual Fund
- 1Y
- +4.3%
- 3Y
- +7.0%
- Vol
- 1.1%
- Max DD
- -0.7%
- Sharpe
- 0.86
- 3Y win
- 0%
- Lower volatility
- Shallower drawdown
- Lower TER
Caveat: Lower trailing returns
Aditya Birla Sun Life Nifty SDL Apr 2027 Index Fund
Aditya Birla Sun Life Mutual Fund
- 1Y
- +5.6%
- 3Y
- +7.4%
- Vol
- 1.4%
- Max DD
- -3.5%
- Sharpe
- 0.36
- 3Y win
- +1%
- Lower volatility
- Shallower drawdown
- Lower TER
Caveat: Lower trailing returns